Author

Elisa Donato

German Cancer Research CenterORCID 0000-0003-3541-9170Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1 Organism:mouse· 1

Frequent Co-Authors

Andreas TrumppiD· 2 shared Aarushi GuptaiD· 1 shared Andy G.X. ZengiD· 1 shared Caitlyn VlasschaertiD· 1 shared Darryl Y. ChaniD· 1 shared Enrique Sanz‐GarcíaiD· 1 shared Frédéric LutoniD· 1 shared Isabelle Mus‐VeteauiD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 31 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Andreas TrumppORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologyTranslational OncologyPeer-reviewedApr 18, 2026

Inhibition of PTCH1 drug efflux activity enhances chemotherapy efficacy against triple negative breast cancer

Sarah Cogoluegnes, Sandra Kovachka, Thierry Dubois…·Isabelle Mus‐Veteau

This study shows that inhibiting PTCH1 drug efflux improves chemotherapy effectiveness in triple-negative breast cancer cells by increasing drug retention and reducing cell migration.

DOI 10.1016/j.tranon.2026.102777

humanbulk RNA-seq

𝕏 PostBluesky

Cancer BiologyCancer ResearchPeer-reviewedNov 11, 2025

Hematopoietic Tet2 inactivation enhances the response to checkpoint blockade immunotherapy

Vincent Rondeau, Suraj Bansal, Marco M. Buttigieg…·Robert J. Vanner

This study shows that hematopoietic Tet2 inactivation improves immune checkpoint blockade response in mice and is associated with better clinical outcomes in melanoma patients with TET2-driven clonal hematopoiesis.

12 citationstop 3%

mousehuman

𝕏 PostBluesky